Targeted therapies have reshaped the management of advanced MTC, with selective RET inhibitors offering improved efficacy and tolerability, and continued research is essential to overcome resistance, expand therapeutic options, and improve patient outcomes.
H. Arain, Azeem Izhar, Rachael Caretti et al.· The Oncologist· 0 citations
There was an increased risk of developing TC in all groups, and Black patients had the highest HR highlighting an area that warrants further investigation, and Black patients had the highest HR highlighting an area that warrants further investigation.
Rachael Caretti, Raj Roy, H. Arain et al.· The American surgeon· 0 citations
Current evidence supports that an association exists between select chemical exposures and TC development, but study limitations prevent any direct link to causation.
Rachael Caretti, H. Arain, Herbert Chen· The Oncologist· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.